Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)
Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Louise Flanagan(University of Leeds), Gordon Cook(University of Leeds), Mark T. Drayson(Institute of Immunology), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Sidra Ellis(King's College - North Carolina), Kim A. Sharp(Institute of Cancer Research), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sarah Brown(University of Leeds), Katrina Walker(University of Leeds), Andrew Hall(University of Leeds), Graham Jackson(Newcastle College), Amy L. Sherborne(Institute of Cancer Research), Amy Price(Royal Free London NHS Foundation Trust), Ruth M. de Tute(St James's University Hospital), Vallari Shah(Bridge Pharma (United States)), James Croft(Institute of Cancer Research)
Cited by 2
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605